Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That article did answer a question I had about the cost of dcvax relative to current treatments. Turns out it's relatively cheap.
I can't read that on my cell phone. Can you provide a quick and dirty TLCR?
At this point it makes no sense to release tld before the holidays are over and the market is paying attention.
If you brpa lot it gives you relief. As in rlf100. They have a significant share of rlftf's future revenue stream.
I'll take 12.8 and be ecstatic. If it does pop on news I'll cash in about 75% of my position as a pullback is a certainty.
I think he dropped a decimal point. Best case is 12.8 bagger, around 5.40 per share. Best case.
There will be a selloff today if NWBO follows the broader market and absent news I expect it will. The Dow will probably be down 2.5 to 3 percent if it follows the European market.
The article also says it's no more deadly than the original.
Bad link. Nothing there.
I own some amrn. They just completed an open trial which showed efficacy and have a phase 3 trial underway in Argentina.
If this ever hits a buck I'm out except for a few thousand shares just in case a miracle happens.
He can have my shot.
Thank you for that. It's encouraging.
1.26 now. Perhaps you have your answer .
Interesting. Piperine is used in many cases to increase uptake of a drug. I take a curcumin supplement and piperine is included. According to articles on the subject it increases uptake of curcumin by 2000%.
It's a niche no other drug is conducting a trial for or they have failed at. Success with severely ill patients will fill a void in treatment. As to your question, they are targeting moderately ill patients with a trial starting in January with an inhaler version of aviptadil.
Perhaps what they're buying is the revenue share of rlf100 that neurorx is taking with it.
The Swiss rlf is up this morning on good volume.
If we do get great news when (if) topline data is released let this be a guide for you as to how you manage your holdings.
https://www.cnn.com/2020/12/11/investing/biotech-stocks-breast-cancer/index.html
Thanks for reposting. I did see your earlier reply but this one is better as it adds some detail.
I'm not basing my post on any cost data as I admit I am totally ignorant of the cost of soc currently. My intent was to elicit information from more knowledgeable board members. I do apologize though for giving learning curve a new talking point to bash the company.
How will insurance handle DCVax?
Yes, I'm jumping the gun by assuming dcvax is approved in order to ask my question. Is there a cost benefit analysis (because the insurance companies will surely do one) between SOC currently and the increased cost of replacing or augmenting it with dcvax? The reason I ask is because I think there may be resistance to implementing the use of dcvax based on the cost.
The NYT puts ivermectin in the same category as hydroxychloroquine. Who ya gonna believe?
I suspect the walkdown today is a result of no news with LL's presentation due tomorrow. Retail investors are bailing on a complete lack of news. I suppose something might be released after hours or in the morning.
Not exactly as big a deal as vfb made it out to be.
Schwab shows trades being taken off the board and reverting to previous price and volume. Not just once but several times. Probably just has to do with software but interesting.
The latest theory for the lack of an eua approval was that the FAA was waiting on full enrollment in the trial. Now that it has been achieved I guess we should find out sometime this week whether that's true or not.
She's scheduled to speak but don't know the topic.
Oopsie!
Marzan, I take Gary's advice to heart. After the debacle with Amarin and the happy talk of buyout and 50 dollars a share or more I'll walk with whatever I can get on the news if it's good and buy back in if it drops back. If it goes through the roof I'll just grin and bear it. Once burned, twice shy.
Thanks. She won't participate without at least topline data I don't think.
When is the next scheduled conference LL is scheduled to speak? Sometime in the next week to ten days I think.
My guess is speculators getting in betting there will be good news. The activity says absolutely nothing about whether or not there is positive news. Just people placing some bets.
Reverse splits of underfunded and revenue deficient stocks, especially pharma stocks, results in share price decreases following a reverse split . The evidence is overwhelming in that respect . It also gives shorts a juicy new target since they can now profit greatly from a 5 or greater dollar stock with plenty of room to run to the downside. Unless a stock split is accompanied by killer results in conjunction with a rs retail investors will be hurt.
Yes. That's intubated though. Says nothing about patients receiving ecmo.
Most patients with COVID-19 in the intensive care unit recover, with a mortality rate of 35.7 percent for those on mechanical ventilation, according to a study published online May 26 in Critical Care Medicine
https://www.practiceupdate.com/content/covid-19-mortality-rate-for-intubated-adults-lower-than-previously-reported/102029#:~:text=Most%20patients%20with%20COVID-19,26%20in%20Critical%20Care%20Medicine.
Thanks. Excellent and timely post.
I believe they're just looking for authorization to create more shares. That wouldn't mean they enter the market immediately. Please correct me if I'm wrong.
It's being delayed pending publication in a prominent medical journal followed by a presentation in the first part of Dec. Either that or the drug doesn't work. Take your pick.